Provention Bio
Provention is a New Jersey-based biopharmaceutical company that researches and develops novel therapeutics for the treatment of autoimmune diseases.
Business Model:
Revenue: $2.8M
Employees: 51-200
Industries / Tags:
Detailed Provention Bio Information
Provention Bio was acquired by
Sanofi.
The acquisition happend on 2023-03-13.
Details of the transaction were not public
Acquirer
Geographic Data
Address: 55 Broad Street
City: Red Bank
State: NJ
Zip: 07701
Country: US
Financial Info
Stage:
post ipo equity
Raised Last:
$35M
Raised Total:$219M
Social
Metrics
1,145,563Website Global Rank
23,657Website Monthly Traffic
Twitter Followers
Description
Provention is a New Jersey-based biopharmaceutical company that researches and develops novel therapeutics for the treatment of autoimmune diseases.
Contact Phone:
+19083360360
Contact Email:
Provention Bio went public on 7/19/2018 on the NASDAQ
Listed Exchange:
NASDAQ
IPO Date:
7/19/2018
Ticker Symbol:
PRVB
IPO Price:
$4/share
Amount Raised:
$64M
Live
Opened: -/share
| EBITDA | - |
| Total Cash | - |
| Total Debt | - |
| Total Revenue | - |
| Total Profit (Gross) | - |
| PE Ratio | - |
| Announced Date | Company | Transaction | Money Raised |
|---|
| Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 1/2017 | Series A | 3 | $28.4M |
Johnson &a; Johnson Innovation JDRF T1D Fund MDB Capital Group Johnson &a; Johnson Innovation Johnson &a; Johnson Innovation JDRF T1D Fund MDB Capital Group Johnson &a; Johnson Innovation |
2/2023 | Post-IPO Debt | $40M |
Hercules Capital, Inc. |
1/2021 | Post-IPO Equity | $100M | 7/2018 | IPO | $65.5M | 7/2022 | Post-IPO Equity | 2 | $60M |
Armistice Capital Sessa Capital Armistice Capital Sessa Capital Armistice Capital Sessa Capital |
2/2023 | Post-IPO Equity | $0 |
Sanofi Sanofi Sanofi Sanofi |
8/2022 | Post-IPO Debt | 1 | $125M |
Hercules Capital Hercules Capital Hercules Capital |
6/2020 | Post-IPO Equity | $110.1M | 6/2017 | Series A | $28.4M | 8/2022 | Post-IPO Debt | $25M |
Hercules Capital, Inc |
2/2023 | Post-IPO Equity | 1 | $35M |
Sanofi Sanofi |
|---|
| Announced Date | Name | Price |
|---|
Employee Departments
Employee States
|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|
